Biohaven

Biohaven is a modern pharmaceutical company that is guided by science and inspired to change the lives of people with unmet medical needs.

[Biohaven @biohaven]

The conversation around obesity is evolving and so is the science.
We’re headed to #ObesityWeek to share research exploring body composition and metabolic health through a poster presentation.
#DaysMatter
#ObesityResearch

[Biohaven @biohaven]

A great few days at #ATA2026 connecting with the thyroid community, sharing our research in Graves’ disease and discussing the science behind our degrader program.
#DaysMatter
#ThyroidResearch
#GravesDisease
#UnmaskGravesDisease

[Biohaven @biohaven]

We’re headed to #ATA2026!
Visit the Biohaven team at Booth #22 to learn more about our degrader program in Graves’ disease, hear about the science behind our approach and connect with the people helping advance this research.
#DaysMatter

[Biohaven @biohaven]

A great #KidneyWk in the books! Thank you to everyone who stopped by Booth #791 and connected with the Biohaven team. We’re grateful to be part of this community.
#DaysMatter
#KidneyResearch

[Biohaven @biohaven]

#NEWS: The @US_FDA has accepted our resubmitted NDA for review of our investigational #SCA treatment and plans to convene an Advisory Committee. This milestone reflects our commitment to the SCA community and people living with this devastating disease.

#DaysMatter

[Biohaven @biohaven]

We’re joining the oncology community at #ESMO26 to share new research from Biohaven. Visit our poster to learn more about the science driving our work in oncology.
#CancerResearch #DaysMatter

[Biohaven @biohaven]

We’re headed to @ASNKidney Kidney Week! Visit Biohaven at Booth #791 to learn more about our research in IgAN. Also, at #KidneyWk, we’ll present preclinical research on our investigational TRAP™ degrader in membranous nephropathy.
#DaysMatter

[Biohaven @biohaven]

How should we approach ADA response characterization as biotherapeutics become increasingly complex? Our Executive Director of Bioanalytical Sciences will explore domain specificity, historical recommendations and future perspectives at the Immunogenicity & Bioassay Summit.

[Biohaven @biohaven]

Exciting progress from our oncology pipeline: clinical data on our investigational FGFR3-directed ADC have been selected for oral presentation at #ENA2026! We look forward to sharing findings from the ongoing Phase 1 study in Barcelona this November.
https://t.co/sml2m9dOvz

[Biohaven @biohaven]

New approaches in oncology are expanding to explore how every component of a medicine can work together to improve precision, durability and therapeutic potential.
#DaysMatter
#Oncology
#CancerResearch
#DrugDevelopment

[Biohaven @biohaven]

We’re looking forward to the conversations at this year’s ABI Sweden Conference! Our Chief Translational Officer will moderate a panel bringing together industry leaders to discuss the next generation of autoimmune medicines.
#DaysMatter
#ABI26

[Biohaven @biohaven]

The Biohaven team is headed to Athens and looking forward to sharing new research through both an oral presentation and a poster presentation at the @IlaeWeb European Epilepsy Congress.
#EEC2026
#DaysMatter
#Epilepsy
#Neurology

[Biohaven @biohaven]

Today, we announced a strategic global licensing and collaboration agreement with SK Biopharmaceuticals, the parent company of @SKLifeScience, focused on advancing our Kv7 platform and opakalim, our lead candidate in development for focal epilepsy.
Read the full announcement: https://t.co/W09tBX7dRO

[Biohaven @biohaven]

In her latest LinkedIn article, our Executive Director of Clinical Operations at Biohaven, reflects on more than two decades in drug development and the lessons she's learned about resilience, collaboration and trusting the scientific process.
Read more: https://t.co/t0rJeBP1Iz

[Biohaven @biohaven]

At #ESMO2026, our team will present new data from our investigational BHV-1530 program, highlighting our continued commitment to advancing innovative approaches in oncology. We look forward to sharing our latest research with the global cancer community. https://t.co/L6B9JZqVyd

[Biohaven @biohaven]

We’re pleased to share that our Executive Vice President and Head of Drug Discovery will host a workshop at the Autoimmune Neuromuscular and Nerve Disorders Drug Development Summit next week in Boston. Learn more: https://t.co/nEntLXx4vC
#DaysMatter

[Biohaven @biohaven]

What excites investigators about BHV-1300? Innovation and the potential to advance Graves’ disease treatment with a targeted, mechanism-based approach. Learn more about our Graves' disease clinical trial: https://t.co/DyzoUjyDhK
#DaysMatter

[Biohaven @biohaven]

In the news: @Neurology_Live featured our Chief Medical Officer discussing the latest data from our investigational epilepsy program and the ongoing need for new treatment options. Read the full feature below.
https://t.co/CXpWf8SYWN
#DaysMatter
#Epilepsy

[NeurologyLive® @neurology_live]

What sets opakalim apart from earlier Kv7 therapies? No off-target GABA potentiation, and that may be the key to its cleaner CNS tolerability profile.

@biohaven CMO Irfan Qureshi, MD breaks it down in a new Q&A🔬👇
https://t.co/apnwxpr4t7

[Biohaven @biohaven]

It was great connecting with the nephrology community at the @ERAkidney Congress in Glasgow.
Thank you to everyone who stopped by our booth to learn more about our TRAP™ degrader and shared meaningful conversations with our team. See you next year!
#ERA26